Optimisation of EGFR TKI efficiency wild-type EGFR lung cancer

被引：0
|
作者：
Raimbourg, Judith [1 ]
Cabart, Mathilde [1 ]
Joalland, Marie-Pierre [1 ]
Decaudin, Didier [2 ]
Deplater, Ludmilla [2 ]
Lanoe, Didier [1 ]
Douillard, Jean-Yves [1 ]
Bennouna, Jaafar [1 ]
Vallette, Francois [3 ]
Lalier, Lisenn [1 ]
机构：
[1] Inst Cancerol Ouest, St Herblain, France
[2] Inst Curie, Paris, France
[3] INSERM, Nantes, France
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2559
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2559
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds
    Huang, Yu
    Chen, Yu
    Mei, Qin
    Chen, Yuan
    Yu, Shiying
    Xia, Shu
    ONCOLOGY REPORTS, 2013, 29 (06) : 2486 - 2492
  • [42] Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases
    Zhang, Yalei
    Yang, Haihong
    Yang, Xinyun
    Deng, Qiuhua
    Zhao, Meilin
    Xu, Xin
    He, Jianxing
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 449 - 453
  • [43] EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
    Tomasini, Pascale
    Brosseau, Solenn
    Mazieres, Julien
    Merlio, Jean-Philippe
    Beau-Faller, Michele
    Mosser, Jean
    Wislez, Marie
    Ouafik, L'Houcine
    Besse, Benjamin
    Rouquette, Isabelle
    Debieuvre, Didier
    Escande, Fabienne
    Westeel, Virginie
    Audigier-Valette, Clarisse
    Missy, Pascale
    Langlais, Alexandra
    Morin, Frank
    Moro-Sibilot, Denis
    Zalcman, Gerard
    Barlesi, Fabrice
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)
  • [44] Cost of care in EGFR mutant versus wild-type non-small cell lung cancer.
    Vusqa, Urwat Til
    Asawa, Palash
    Miller, Katherine
    Sethi, Ashish
    Rodriguez, Robin Raquel
    Friday, Andrew
    Finley, Gene Grant
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
    Hao Gong
    Yongwen Li
    Yin Yuan
    Weiting Li
    Hongbing Zhang
    Zihe Zhang
    Ruifeng Shi
    Minghui Liu
    Chao Liu
    Chen Chen
    Hongyu Liu
    Jun Chen
    BMC Cancer, 20
  • [46] EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
    Gong, Hao
    Li, Yongwen
    Yuan, Yin
    Li, Weiting
    Zhang, Hongbing
    Zhang, Zihe
    Shi, Ruifeng
    Liu, Minghui
    Liu, Chao
    Chen, Chen
    Liu, Hongyu
    Chen, Jun
    BMC CANCER, 2020, 20 (01)
  • [47] Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status
    Yu, Xiaoqing
    Fan, Yun
    MEDICINE, 2019, 98 (03)
  • [48] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
  • [49] SLK Causes Resistance to EGFR-TKI in Lung Cancer
    Ashraf, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2371 - S2372
  • [50] An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type.
    Wang, F.
    Wang, J.
    Bai, H.
    Zhao, J.
    Wang, Z.
    Zhuo, M.
    An, T.
    Duan, J.
    Yang, L.
    Wu, M.
    Wang, Y.
    Wang, S.
    Liu, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345